Alzforum highlights the new Nature Medicine paper co-authored by Teal Rise co-founder Tony Wyss-Coray, focusing on how APOE genotype shapes the biological age of astrocytes and macrophages — and how youthful astrocytes appear to protect even APOE4 homozygotes from Alzheimer's.
Alzforum has published an in-depth feature on the recent Nature Medicine paper co-authored by Teal Rise co-founder Tony Wyss-Coray, "Does APOE4 Prematurely Age Astrocytes?". The piece walks through how plasma proteomics — more than 7,000 proteins measured in 60,542 people across the GNPC, UK Biobank, and the 1946 National Survey of Health and Development — can be read at cellular resolution to estimate the biological age of more than 40 cell types from a single blood draw.
A central thread of the coverage is the relationship between APOE genotype and cell-type-specific aging. APOE4 carriers tend to have "older" astrocytes but "younger" macrophages, while APOE2 carriers show the inverse pattern. The differences in average age gap are subtle at the population level, but the tails of the distribution are clinically striking: among APOE4 homozygotes in the UK Biobank with extremely old astrocytes, 38% developed Alzheimer's over 15 years of follow-up, versus 13% in APOE4 homozygotes with only modestly older astrocytes — and none of the 23 APOE4 homozygotes with notably youthful astrocytes developed the disease.
Alzforum also highlights the broader reach of the framework beyond Alzheimer's. People with exceptionally aged skeletal myocytes were roughly three times more likely to develop ALS than those with normally-aged muscle cells, and ALS cases themselves showed accelerated aging not only in skeletal muscle but also in cardiomyocytes — consistent with previously reported cardiac involvement in the disease. Alzheimer's was additionally linked to accelerated aging of oligodendrocyte precursor cells, pancreatic endocrine cells, proximal enterocytes, and inhibitory neurons, and astrocyte aging tracked with plasma p-tau217.
External commentators quoted in the piece — Jeffrey Dage (Indiana University), Kanta Horie (Washington University in St. Louis), Vivek Swarup (UC Irvine), and Julia TCW (Boston University) — describe the work as a conceptual advance for the field, moving beyond chronological, brain, or organ age toward cell-resolved estimates of biological vulnerability. Several note that astrocyte aging may itself become a target for drug development and lifestyle intervention, and that combining cellular aging clocks with markers such as plasma p-tau217 could anchor a more mechanistically grounded model of Alzheimer's progression.
We're grateful to Alzforum and reporter George Heaton for the careful coverage, and to the commentators for engaging so substantively with the work. Seeing cell-level aging clocks discussed alongside established AD biomarker frameworks is exactly the kind of conversation we hope this line of research will continue to drive.
Read the full article on Alzforum.
Teal Rise